Plasminogen activation and cancer
- PMID: 15841311
- DOI: 10.1160/TH05-01-0054
Plasminogen activation and cancer
Abstract
Breakdown of the extracellular matrix is crucial for cancer invasion and metastasis. It is accomplished by the concerted action of several proteases, including the serine protease plasmin and a number of matrix metalloproteases. The activity of each of these proteases is regulated by an array of activators, inhibitors and cellular receptors. Thus, the generation of plasmin involves the pro-enzyme plasminogen, the urokinase type plasminogen activator uPA and its pro-enzyme pro-uPA, the uPA inhibitor PAI-1, the cell surface uPA receptor uPAR, and the plasmin inhibitor alpha(2)-antiplasmin. Furthermore, the regulation of extracellular proteolysis in cancer involves a complex interplay between cancer cells and non-malignant stromal cells in the expression of the molecular components involved. For some types of cancer, this cellular interplay mimics that observed in the tissue of origin during non-neoplastic tissue remodelling processes. We propose that cancer invasion can be considered as uncontrolled tissue remodelling. Inhibition of extracellular proteases is an attractive approach to cancer therapy. Because proteases have many different functions in the normal organism, efficient inhibition will have toxic side effects. In cancer invasion, like in normal tissue remodelling processes, there appears to be a functional overlap between different extracellular proteases. This redundancy means that combinations of protease inhibitors must be used. Such combination therapy, however, is also likely to increase toxicity. Therefore for each type of cancer, a combination of protease inhibitors that is optimised with respect to both maximal therapeutic effect and minimal toxic side effects need to be identified.
Similar articles
-
Plasmin/plasminogen system in colorectal cancer.World J Surg. 2002 Jul;26(7):767-71. doi: 10.1007/s00268-002-4050-8. Epub 2002 Apr 30. World J Surg. 2002. PMID: 11965442 Review.
-
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.Thromb Haemost. 1997 Jul;78(1):285-96. Thromb Haemost. 1997. PMID: 9198168 Review.
-
Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.Scand J Gastroenterol. 2005 Jul;40(7):783-93. doi: 10.1080/00365520510015665. Scand J Gastroenterol. 2005. PMID: 16109653
-
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.Int J Oncol. 2009 Jan;34(1):15-23. Int J Oncol. 2009. PMID: 19082473
-
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
Cited by
-
Identification of therapeutically potential targets and their ligands for the treatment of OSCC.Front Oncol. 2022 Sep 20;12:910494. doi: 10.3389/fonc.2022.910494. eCollection 2022. Front Oncol. 2022. PMID: 36203433 Free PMC article.
-
Gender affects skin wound healing in plasminogen deficient mice.PLoS One. 2013;8(3):e59942. doi: 10.1371/journal.pone.0059942. Epub 2013 Mar 20. PLoS One. 2013. PMID: 23527289 Free PMC article.
-
Serpins in thrombosis, hemostasis and fibrinolysis.J Thromb Haemost. 2007 Jul;5 Suppl 1(Suppl 1):102-15. doi: 10.1111/j.1538-7836.2007.02516.x. J Thromb Haemost. 2007. PMID: 17635716 Free PMC article. Review.
-
RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells.Mol Cell. 2009 Aug 28;35(4):511-22. doi: 10.1016/j.molcel.2009.08.002. Mol Cell. 2009. PMID: 19716794 Free PMC article.
-
Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway.Endocrinology. 2008 May;149(5):2637-45. doi: 10.1210/en.2007-1096. Epub 2008 Jan 31. Endocrinology. 2008. PMID: 18239069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous